Ziopharm Oncology In (NASDAQ:ZIOP) shares traded during most recent session to reach at the closing price of $2.72. The stock exchanged hands on average of 1.15 Million shares, yielding a market cap of $400.41 Million. Wall Street analysts covering the stock are projecting that the stock will reach $4.25 within the next 52-weeks. The mean target projections are based on 2 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Ziopharm Oncology In (NASDAQ:ZIOP) high price target of $5.5 and with a conservative view have low price target of $3.

JP Morgan “Downgrades” Ziopharm Oncology In (NASDAQ:ZIOP) in a research note issued to investors on 6/18/18 to Underweight with price target of $0.

Additionally on 6/01/17 H.C. Wainwright “Initiates Coverage On” Ziopharm Oncology In (NASDAQ:ZIOP) to Buy setting price target at $9.5 and on 8/10/16 Wells Fargo “Upgrades” the stock to Market Perform at $. Furthermore on 6/02/16 Raymond James “Initiates Coverage on” the stock to Market Perform at $.

On the other hand the company has Relative Strength Index (RSI 14) of 38.44 along with Average True Range (ATR 14) of 0.2, Consequently Ziopharm Oncology In (NASDAQ:ZIOP)’s weekly and monthly volatility is 8.02%, 6.95% respectively. The company’s beta value is at 1.38.

In terms of Buy, Sell or Hold recommendations, Ziopharm Oncology In (NASDAQ:ZIOP) has analysts’ mean recommendation of 3. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Ziopharm Oncology In (NASDAQ:ZIOP)’s minimum EPS for the current quarter is at $-0.14 and can go high up to $-0.07. The consensus mean EPS for the current quarter is at $-0.11 derived from a total of 4 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.13 earnings per share for the same quarter during last year.

Previously Ziopharm Oncology In (NASDAQ:ZIOP) reported $-0.12 earnings per share (EPS) for the quarter, meeting the consensus estimate of $-0.12 by $0. The company posted an earnings surprise of 0%.

Currently Ziopharm Oncology In (NASDAQ:ZIOP)’s shares owned by insiders are 0.9%, whereas shares owned by institutional owners are 40.9%. However the six-month change in the insider ownership was recorded 0%, as well as three-month change in the institutional ownership was recorded 0.88%.

Ziopharm Oncology In (NASDAQ:ZIOP)’s trailing twelve month revenues are $3.3 Million, whereas its price to sales ratio for the same period is 121.34. Its book value per share for the most recent quarter is $-0.99 while its price to book ratio for the same period is 0, as for as the company’s cash per share for the most recent quarter is $0.27, however its price to cash per share ratio for the same period is 9.91. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.